UK Markets closed

Ambu A/S (AMBBY)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
10.71+0.07 (+0.66%)
At close: 02:44PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close10.64
Open10.71
Bid0.00 x 0
Ask0.00 x 0
Day's range10.71 - 10.71
52-week range9.30 - 35.30
Volume1,677
Avg. volume6,140
Market cap2.717B
Beta (5Y monthly)0.43
PE ratio (TTM)71.88
EPS (TTM)0.15
Earnings dateN/A
Forward dividend & yield0.04 (0.41%)
Ex-dividend date15 Dec 2021
1y target estN/A
  • Globe Newswire

    Preliminary results for Q3 2021/22, current trading (July) and launch of cost reduction program. Full-year 2021/22 guidance revised

    Preliminary Q3 organic revenue growth was 8%. Visualization organic growth was 0%, Anaesthesia organic growth was 14%, and Patient Monitoring & Diagnostics (PMD) organic growth was 20%.Current trading for July, the first month of the last quarter of the financial year 2021/22, showed an organic revenue growth of 6%, significantly below expectations.Decision to launch a cost reduction program expected to result in an annualised savings of DKK 250m from the financial year 2022/23. One-off expenses

  • Globe Newswire

    Britt Meelby Jensen appointed new CEO of Ambu

    The Board of Directors of Ambu A/S has appointed Britt Meelby Jensen as new Chief Executive Officer (CEO). Britt Meelby Jensen has served as board member of Ambu since 2019, a position she will step down from when she takes over the position as CEO on 20 May 2022 and replaces Juan Jose Gonzalez who will leave Ambu after three years and support the new CEO in the transition as needed. “Since Juan Jose Gonzalez joined as CEO in 2019, Ambu has made good progress and achieved important milestones on

  • Globe Newswire

    Interim report for Q2 2021/22 and the half-year

    For Q2, Ambu posted organic revenue growth of 8% with reported growth of 12%. The macroeconomic headwinds with inflation and continued congestion of the global supply chain are further increasing our costs of production and distribution. We also expect a return of elective procedures to above 2019 levels, but with lower benefit from pent-up demand due to hospital labour shortages. With 70% of our revenue coming from elective procedures, we adjust our financial outlook downward to organic growth